目的 探讨三子止咳胶囊联合布地奈德粉吸入剂治疗慢性阻塞性肺疾病稳定期的临床疗效。方法 选择2017年5月-2018年11月在濮阳市人民医院就诊的82例慢性阻塞性肺疾病患者作为研究对象，按照随机数字表法分为对照组和治疗组，每组各41例。对照组雾化吸入布地奈德粉吸入剂，1吸/次，2次/d。治疗组在对照组治疗的基础上口服三子止咳胶囊，0.6 g/次，3次/d。两组患者连续治疗3个月。观察两组的临床疗效，比较两组的肺功能、炎症因子。结果 治疗后，对照组和治疗组的总有效率分别为82.93%、95.12%，两组比较差异有统计学意义（P<0.05）。治疗后，两组的第一秒用力呼气容积（FEV1）、FEV1/用力肺活量（FVC）、最大呼气流速（PEF）、FEV1预计值均显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组的FEV1、FEV1/FVC、PEF、FEV1预计值均明显高于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组的C反应蛋白（CRP）、细胞间黏附分子-1（ICAM-1）、肿瘤坏死因子-α（TNF-α）、白细胞介素-17（IL-17）水平均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组的CRP、ICAM-1、TNF-α、IL-17水平均明显低于对照组，两组差异有统计学意义（P<0.05）。结论 三子止咳胶囊联合布地奈德粉吸入剂治疗慢性阻塞性肺疾病稳定期具有较好的临床疗效，能改善患者的肺功能，减轻炎症反应，具有一定的临床推广应用价值。

Objective To explore the clinical efficacy of Sanzi Zhike Capsules combined with Budesonide Powder for inhalation in treatment of stable chronic obstructive pulmonary disease. Methods Patients (82 cases) with stable chronic obstructive pulmonary disease in Puyang People's Hospital from May 2017 to November 2018 were randomly divided into control and treatment groups, and each group had 41 cases. Patients in the control group were atomization inhalation administered with Budesonide Powder for inhalation, 1 suction/time, twice daily. Patients in the treatment group were po administered with Sanzi Zhike Capsules on the basis of the control group, 0.6 g/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and pulmonary function and inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.93% and 95.12%, respectively, and there was difference between two groups (P < 0.05). After treatment, FEV1, FEV1/FVC, PEF, and FEV1 predicted in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the pulmonary function indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of CRP, ICAM-1, TNF-α, and IL-17 in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the inflammatory factors indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Sanzi Zhike Capsules combined with Budesonide Powder for inhalation has clinical curative effect in treatment of stable chronic obstructive pulmonary disease, can improve the lung function of patients and reduce the inflammatory reaction, which has a certain clinical application value.

R974